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Background: Solid pseudopapillary tumour (SPT) of the pancreas is a rare neoplasm of low malignant
potential. The pathogenesis and guidelines for its treatment remain unclear. This study was designed to
evaluate the diagnosis, surgical treatment and prognosis of SPT.
Study design: A retrospective study during the period between January 1995 to October 2012.
Patients and method: Cases with SPTs treated at our institution were reviewed. Demographic data, clinical
manifestations, radiological, surgical, and pathological records were reviewed for patients with SPT.
Results: Twenty four patients with SPT were identiﬁed (22 women and 2 men with a mean age
24.83  8.66 (12e52 years). The tumour was located in the head in (50%) and in the body (8.3%) and in
the tail (41.7%). The mean size was 9.2  5.3 (3e25 cm). The main clinical presentation was abdominal
pain in (83.3%). All 24 patients had curative resection including pancreaticoduodenectomy (50%), central
pancreatectomy (8.3%) and distal pancreatectomy (41.7%). Sex, age, symptoms, tumour size, CT image
and tumour markers were not signiﬁcant clinical factors to predict SPT with malignant behavior.
The recurrence rate was (8.3%) after 5 years postoperatively. No hospital mortality, all patients except
2 patients (8.3%) were alive at follow up period. The estimated 1, 3, and 5 year survival rate was 95%, 95%,
and 88%.
Conclusion: SPT are rare neoplasms with malignant potential. Aggressive surgical resection is needed
even in presence of local invasion, and also for recurrence as patients had a good long term survival.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Solid pseudopapillary tumour of the pancreas (SPT) is an
uncommon neoplasm of the pancreas representing about 1e3%
of exocrine pancreatic neoplasm, usually occur in young females
in the second to fourth decades of life.1e4 Since 1959, over 500
cases of SPT of pancreas have been reported. Recently, there has
been a steady increase in number of SPT of the pancreas, with
more than two third of the total cases described in the last 10
years.5e8
Solid pseudopapillary tumour of the pancreas (SPT) was ﬁrst
described by Franz in 1959 as a papillary tumour of the pancreas.lication in any other journal
ublication in another journal
hed previously in any media.
bile).
Nakeeb).
ciates Ltd. Published by Elsevier LtThe ﬁrst surgical resection of a SPTwas performed by Grosfelad and
described by Hamoudi in 1970.9,10 Historically SPT has been deﬁned
using terms such as papillary epithelial neoplasm, solid and cystic
tumour, solid and papillary epithelial neoplasm, papillary and
cystic neoplasm, Hamoudi tumour and Franz tumour.9e12 In 1996
the World Health Organization (WHO) formally named it as SPT
and reclassiﬁed it to be a kind of boundary malignant tumour with
unclear biological behavior.1
SPT had aroused a great interest and awareness in the last de-
cades, as several clinical studies were published, however, the
pathogenesis and guidelines for SPT management remain un-
clear.2e5,8 The clinical and pathological characteristics of SPT are
different from pancreatic cancer. It has low malignant potential,
and rarely metastasizes.4 SPN are most often benign however, up to
20% show a malignant character.8,13 Even in the presence of
disseminated disease, the clinical course is usually favorable.2e5
The overall survival rate after 5 years and 10 years post surgical
resection were 95e98% and 93% respectively including patients
with malignant disease.4,8d. All rights reserved.
Table 1
Patients chacteristics and clinical presentation.
Total cases Benign
behavior
Malignant
behavior
Age (Years) 24.83  8.66
(12e52)
24.7  5.05
(15e33)
25.33  16.1
(12e52)
0.87
Sex
Male 2 (8.3%) 1 (5.6%) 1 (16.7%) 0.39
Female 22 (91.7%) 17 (94.4%) 5 (83.3%)
Symptoms duration 4.7  2.6 4.88  2.7 4.5  2.3 0.81
BMI
<25 21 (87.5%) 15 (83.3%) 6 (100%) 0.28
>25 3 (12.5%) 3 (16.7%) 0
History of abdominal
trauma
0 0 0
History of pancreatitis 0 0 0
Clinical picture
Asymptomatic 2 (8.3%) 2 (11.1%) 0 0.39
Abdominal pain 20 (83.3%) 15 (83.3%) 5 (83.3%) 1
Back pain 4 (16.7%) 1 (5.6%) 3 (50%) 0.01
Nausea and vomiting 2 (8.3%) 2 (11.1%) 0 0.39
Jaundice 2 (8.3%) 1 (5.6%) 1 (16.7%) 0.39
Loss of weight 3 (12.5%) 2 (11.1%) 1 (16.7%) 0.72
Palpable abdominal
mass
8 (33.3% 5 (27.8%) 3 (50%) 0.31
Laboratory data
S. bilirubin 1.3  2.02 1.19  1.96 1.68  2.36 0.37
Hemoglobin 9.7  0.9 9.6  0.98 9.8  1.1 0.95
S. amylase 133  52.3 135.2  58.5 127.5  30 0.44
Blood sugar 86  5.3 85.2  5.3 88.3  9.9 0.81
Tumour marker
CEA
<5 19 (79.2%) 14 (77.8%) 5 (83.3%) 0.77
>5 5 (20.8%) 5 (22.2%) 1 (16.7%)
Ca19-9
<37 20 (83.3%) 15 (83.3%) 5 (83.3%) 1
>37 4 (16.7%) 3 (16.7%) 1 (16.7%)
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eastern countries, but the incidence in different geographic areas
has not been reported.8,11,14
The aim of this study was to examine the clinicopathologic
characteristics of SPT of the pancreas, including the effect of risk
factors on tumour behavior and survival.
2. Patients and method
2.1. Patients
A retrospective study was carried out including all patients who underwent
surgery for Solid pseudopapillary tumour of the pancreas (SPT) in the period
from January 1995 to October 2012 at the Gastroenterology Surgical Center, Man-
soura University, Egypt. The Institutional Review Board granted approval for the
protocol.
2.2. Method
Patients with clinical characteristics, radiological, surgical, and pathological
records were reviewed for these patients. The hospital medical records were
searched to determine the patient’s age, gender, presenting symptoms, and any past
history of pancreatitis, or diabetes mellitus. These data were collected manually
from our hospital medical records by all authors.
2.2.1. Clinical characteristics
Clinical presentation included abdominal pain, vomiting, jaundice, loss of
weight, or abdominal mass however, some cases were asymptomatic. Routine blood
investigations were performed including hepatic and renal function tests. Cardio-
pulmonary assessment were done for all patients. Serum amylase and tumour
markers (CEA, and CA19-9) were done in some patients preoperatively.
2.2.2. Radiological data
The morphology of the pancreatic cysts was collected from the CT ﬁnding and
the operative report. CT was performed for all patients to show the largest diameter
of the cyst, site, calciﬁcation, wall thickness and solid component. Cyst ﬂuid was
collected by intraoperative needle aspiration or, when complete resection was
planned, by needle aspiration immediately after surgical removal of the cyst.
Magnetic resonance image (MRI) for patients presented by recurrent lesion
after resection. Magnetic resonance cholangiopancreatography (MRCP) for patients
presented by obstructive jaundice.
2.2.3. Operative procedures
Surgical treatment depends on the location and extension of the cyst. Distal
pancreatectomywas performed for cyst located in the tail. Lesions of the body of the
pancreas were treated by central pancreatectomy, with closing of proximal
pancreatic segment and drainage of the distal segment with a Roux en Y pan-
creaticojejunostomy. Tumours of the head and or uncinate process were treated by
pancreatoduodenectomy (PD), with or without pylorus preservation, with pan-
creaticogastrostomy (PG) or pancreaticojejunostomy (PJ) based on surgeon’s pref-
erence. Frozen section of the surgical margins had an important role in the
intraoperative management of cysts in some patients to determine free safety
margin. Sandostatin was given for all patients postoperatively. Operative time,
morbidity, and hospital stay were collected from medical records. Follow up data
including recurrence, morbidity and survival information were collected.
Postoperative complications were deﬁned as complications occurring within 30
days of surgery as described below. Postoperative pancreatic ﬁstula was deﬁned as
proposed by International Study Group of Pancreatic Fistula (ISGPF) as any
measurable volume of ﬂuid on or after POD 3 with amylase content greater than 3
times the serum amylase activity, and classiﬁed into grades A, B, C.15e17 Biliary leak
was deﬁned as the presence of bile in the drainage ﬂuid that persists to POD 4.
Delayed gastric emptying was deﬁned as output from a nasogastric tube of greater
than 500 ml per day that persisted beyond POD 10, the failure to maintain oral
intake by POD 14, or reinsertion of a nasogastric tube.15,17
2.2.4. Pathological data
SPT was diagnosed pathologically based on gross andmicroscopic appearance of
tumour. Specimens were ﬁxed in 5% buffered formalin and embedded in parafﬁn.
Histopathologic preparations were made using routine hematoxylineeosin staining.
In cases in which the diagnosis of SPT was unclear immunohistochemical staining
was performed to conﬁrm the diagnosis. All pathologic specimens were reviewed by
different pathologist.
2.3. Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded sections were deparafﬁnized, and dehy-
drated. Steam-heat was used to retrieve antigens, for 40 min at 98 C in citratebuffer (pH 7.0). Monoclonal anti-CD 99 (MS-294-R7, Thermo Fisher Scientiﬁc,
Fremont, CA, USA), Vimentin (Clone VIM 3B4, N1583, DAKO, Glostrup, Denmark),
Synaptophysin (MS-1150R7, Thermo Fisher Scientiﬁc, Fremont, CA, USA), and
Cytokeratin (clones AE1/AE3, N1590, DAKO, Glostrup, Denmark) were used as
primary antibodies. The antigeneantibody reaction was visualized with the Dako
REAL EnVision system, (DAKO, Glostrup, Denmark) using 3, 3-diaminobenzidine
(DAB) as a chromogen. The sections were counterstained with Mayer’s
hematoxylin.
Each SPT was classiﬁed according to the WHO as either SPT with an uncertain
potential for malignancy or solid pseudopapillary carcinoma SPC.1,2 Although
criteria of malignancy have not yet been clearly established, it appears that peri-
neural invasion, angioinvasion, deep invasion into the surrounding tissue or distant
metastasis indicate malignant behavior, and such lesions should be classiﬁed as SPC.
A high degree of nuclear atypia, mitotic activity and prominence of necrobiotic cell
nests (cells with pyknotic nuclei and eosinophilic cytoplasm) were reported to be
associated with malignancy.1
Patients were further classiﬁed using the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) tumour-node-metastasis (TNM)
residual tumour classiﬁcation system: R0 (no residual), R1 (microscopic residual
tumour), or R2 (macroscopic residual tumour).18
2.3.1. Follow up
In our center, after surgery, patients were followed up after 2 weeks, 6 months,
one year then annually until death or were lost to follow up study. Each visit
included a clinical examination, routine laboratory investigation (including com-
plete blood picture, liver function, blood sugar, amylase, and tumour markers CEA,
CA19-9), abdominal and pelvic ultrasound, abdominal and pelvic computed to-
mography (CT) and Magnetic resonance image (MRI) for patients presented by
recurrent lesion after resection.
Patients’ follow up was based on the medical records and their last hospital
visits and personal communication conducted by telephone calls.
Statistical analysis of the data in this study was performed using SPSS software,
version 17 (Chicago, IL). For continuous variables, descriptive statistics were calcu-
lated andwere reported asmean standard deviation (SD) or as medianwith range.
Categorical variables were described using frequency distributions. Independent
sample t-test was used to detect differences in the means of continuous variables
and Chi-square test was used in cases with low expected frequencies. P values< 0.05
were considered signiﬁcant.
Table 2
Cysts chacteristics and radiological ﬁnding.
Total cases Benign
behavior
Malignant
behavior
Tumour size (Cm) 9.2  5.3
(3e25)
8.7  5.2
(3e25)
10.5  5.6
(5e20)
0.69
Tumour location
Head 12 (50%) 8 (44.4%) 4 (66.7%) 0.53
Body 2 (8.3%) 2 (11.1%) 0
Tail 10 (41.7%) 8 (44.4%) 2 (33.3%)
CT ﬁnding
Well demarcated 24 (100%) 18 (100%) 6 (100%)
Tumour nature
Solid 4 (16.7%) 3 (16.3%) 1 (16.7%)
Cystic 3 (12.5%) 2 (11.1%) 0 0.93
Mixed 17 (70.8%) 15 (83.3%) 5 (83.3%)
Presence of calciﬁcations 6 (25%) 5 (20.8%) 1 (16.7%) 0.52
Presence of hemorrhage &
necrosis
18 (75) 14 (77.8%) 4(66.7%) 0.59
Postoperative pathology
Peripancreatic inﬁltration 5 (20.5%) 0 1 (20.5%) 0.0001
Perineural inﬁltration 3 (12.5%) 0 3 (50%) 0.001
Capsular invasion 1 (20.5%) 0 1 (16.7%) 0.07
Cellular atypia 3(20.5%) 0 3 (50%) 0.001
Fig. 2. A 18 years old female presented by abdominal pain. Abdominal CT demonstrate a
cystic lesion 4  5 cm in body of pancreas. Mid-pancreatectomy was done for this case.
Fig. 3. A 21 years old female presented by abdominal pain and palpable abdominal
mass. Abdominal CT demonstrate a large heterogeneous mass 25  13 cm in the tail of
pancreas encroaching on the body of the pancreas.
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3.1. Demographic data
Between January 1995 to October 2012, a total of 765 patients
underwent pancreatic surgery at the Gastroenterology Surgical
Center, Mansoura University, Egypt including 24 (3.13%) who un-
derwent surgery for pathologically conﬁrmed SPT.
There were 22 women (91.7%) and two men (8.3%), with a mean
age (24.83  8.66 range, 12e52 years). The neoplasm was single in
all patients, and the mean diameter of tumour was 9.2  5.3 cm
(range 3e25 cm). The most common sites of the tumour were
pancreatic head in 12 patients (50%), body in 2 patients (8.3%) and
tail in 10 patients (41.7%). (Tables 1 and 2) (Figs. 1e3).
The symptoms were none speciﬁc and presence of two or more
symptoms was usually found. Clinical presentation was abdominal
pain in 20 patients (83.%), nausea and vomiting in 2 patients (8.3%),
weight loss in 3 patients (12.5%), back pain in 4 patients (16.7%),
jaundice in 2 patients (8.3%), palpable abdominal mass in 8 patients
(33.3%). Two patients (8.3%) whose SPT was found on US were
asymptomatic. None of patients had history of trauma or pancre-
atitis. The patients had the mean symptom duration of 4.7  2.6
months (range, one month to 11 months). (Table 1)Fig. 1. a): A 28 years old female presented by abdominal pain. Abdominal CT demonstrate a
presented by abdominal pain and palpable abdominal mass. Abdominal CT demonstrate a3.2. Preoperative examination
3.2.1. Laboratory
The level of tumour markers such as CEA was slightly increased
in 5 patients (20.8%) and normal in 19 patients (79.2%). The level of
tumourmarkers such as CA19-9 was slightly increased in 4 patientslarge heterogeneous mass 5  6 cm in the head of pancreas. (b): A 14 years old female
large well demarcated heterogeneous mass 11  8 cm in the head of pancreas.
Fig. 4. A 12 years old female presented by obstructive jaundice and abdominal pain.
MRCP Revealing dilated common bile duct and pancreatic duct with mass 4  3 cm in
the head of the pancreas. Pancreaticoduodenectomy was done.
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serum amylase was normal in all patients. Blood sugar levels were
within normal ranges in all patients (Table 1).
Total bilirubin concentrations werewithin normal in all patients
in the study except two patients who had picture of obstructive
jaundice. The hemoglobin level is slightly decreased below 10 gm %
in 13 patients (54.16%). The mean level of hemoglobin was
9.7  0.9 gm% (range, 8e11 gm%). Table 1.
3.2.2. Radiological imaging
Abdominal ultrasound and CT showed the typical features of SPT
in 17 patients (70.8%). The tumour appeared as awell circumscribedTable 3
Surgical outcome and follow up.
Total cases B
Type of operation
Pancreaticoduodenectomy 12 (50%) 8
Classical 11 (45.8%) 7
Pylorus preserving 1 (4.2%) 1
Central pancreatectomy 2 (8.3%) 2
Distal pancreatectomy 10 (41.7%) 8
Pancreatic duct diameter 2.7  0.97 (2e5) 2
Common bile duct diameter 6.9  3.1 (3e16) 6
Pancreatic texture
Soft 20 (83.3%) 1
Firm 4 (16.7%) 4
Duration of operation 4.5  1.5 (2.5e7) 4
Postoperative hospital stay 9.5  4.4 (5e24) 9
Blood loss 403.33  210.7 (200e1000) 3
Time to resume oral feeding 5.79  2.84 (4e15) 5
Postoperative hospital stay 9.5  4.4 (5e24) 9
Blood transfusion 0.54  0.65 (0e2) 0
Postoperative complications
Pancreatic leakage 4 (16.7%) 2
Grade A 2 (8.3%) 1
Grade B 2 (8.3%) 1
Biliary leakage 5 (20.8%) 4
Delayed gastric emptying 1 (4.2%) 0
Wound infection 1 (4.2%) 1
Mean follow up period 71.62  57. 29 (1e180) 6
Recurrence rate 2 (8.3%) 0
Mortality 2 (8.3%) 0
Follow up Billirubin 1.05  0.7 (0.4e3) 1
Follow up blood sugar 99.04  25.8 (78e160) 9
Follow up hemoglobin 11  1.1 (8e13) 1
Follow up amylase 100.7  60.7 (10e220) 9lesion, capsulated with a mixed cystic and solid component in 17
patients (70.8%), solid only in 4 patients (16.7%) and cystic
component only in 3 patients (12.5%). Calciﬁcations were present in
6 patients (25.5%), while hemorrhage and/or necrosis were detec-
ted in 18 patients (75%) (Table 2).
Magnetic resonance cholangiopancreatography (MRCP) was
done in two cases presented by obstructive jaundice and revealed
dilated common bile duct (CBD), dilated intrahepatic duct, no
dilated pancreatic duct, and well circumscribed swelling with
heterogeneous appearance (Fig. 4). Endoscopic retrograde chol-
angiopancreatography (ERCP) was not done for any case.
None of the patients had a deﬁnite preoperative diagnosis, and a
correct diagnosis was made for 15 patients. Mistakes in diagnosis
occurred in 9 cases. They included pancreatic adenocarcinoma
(n ¼ 3), mucinous cystic neoplasm (n ¼ 5), and cholodochal cyst
(n ¼ 1).
3.2.3. Surgical intervention
All patients underwent surgical exploration. Neither ascites nor
metastases were found during exploration. The choice of surgical
procedures depended on the position of tumour in the pancreas.
Seventeen patients (70.8%) with lesions in the head underwent
pancreaticoduodenectomy (16 underwent Whipple operation and
one pylorus preserving PD). Two patients (8.3%) underwent central
pancreatectomy for lesions located in the body. The remaining ﬁve
patients (20.8%) underwent distal pancreatectomy. The mean oper-
ative time was 4.5  1.5 (range, 2.5e7 h). The mean pancreatic duct
diameter was 2.7  0.97 (2e5 mm) and the mean diameter of CBD
was 6.9  3.1 (range, 3e16). Blood transfusion was needed in eleven
patients during operation. Themeanpostoperative staywas 9.5 4.4
days (range, 5e24 days). The mean time to resume oral feeding was
5.79  2.84 days postoperatively (range, 4e15 days). Table 3
During surgery, frozen section biopsies were performed for 5
patients. four tumours were diagnosed as SPT and one as papillaryenign behavior Malignant behavior
(44.4%) 4 (66.7%)
(%) 4 (83.3%)
(5.6%) 0 0.53
(11.1%) 0
(44.4%) 2 (33.3%)
.7  1.1 (2e5) 2.6  0.54 (2e3) 0.86
.05  1.7 (3e10) 9.5  4.7 (5e16) 0.01
4 (77.8%) 6 (100%) 0.21
(22.2%) 0
.3  1.3 (2.5e6) 5.4  1.8 (2.5e7) 0.09
.33  4.45 (5e24) 10.2  4.4 (8e19) 0.69
57.2  201.6 (200e1000) 541.7  188 (250e750) 0.06
.72  2.51 (4e15) 6  3.94 (4e14) 0.84
.33  4.45 (5e24) 10.2  4.4 (8e19) 0.69
.4  0.7 (0e2) 0.83  0.4 (0e2) 0.2
(11.1%) 2 (33.3%) 0.21
(5.6%) 1 (16.7%) 0.45
(5.6%) 1 (16.7%)
(22.2%) 1 (16.7%) 0.77
1 (16.7%) 0.07
(5.6%) 0 0.56
7.27  52.63 (1e180) 84.66  37.45 (5e160) 0.53
2 (33.3%) 0.01
2 (33.3%) 0.01
.12  0.78 (0.4e3) 0.83  0.33 (0.5e1.2) 0.39
9.6  27.2 (78e160) 97.5  23.8 (82e145) 0.87
1.2  0.94 (10e13) 10.33  1.36 (8e12) 0.08
8.8  46.86 (10e160) 106  97.1 (10e220) 0.8
Fig. 5. (a, b): The tumours were well encapsulated and well demarcated from the pancreas. The cut surface showed alternating solid and cystic areas with areas of hemorrhage and
necrosis. The cystic cavities were irregular and lined by friable tissue. The catheter in the common bile duct.
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no surgical mortality. Postoperative complications occurred in 11
patients (45.8%). Four patients (16.7%) had pancreatic leakage
(two patients had pancreatic leakage grade A, and the other two
developed grade B pancreatic ﬁstula). biliary leakage occurred in
ﬁve patients (20.8%). one patient had wound infection and another
one developed delayed gastric emptying (Table 3).
3.2.4. Pathological features
Tumours were generally large and spherical, varied in colour
from tan to yellow. The tumours were well encapsulated and usu-
ally well demarcated from the pancreas in all patients. The cut
surface showed alternating solid and cystic areas with areas of
hemorrhage. The cystic cavities were irregular and lined by friable
tissue (Fig. 5). Microscopically tumour cells arranged around
ﬁbrovascular stalks forming pseudopapillary pattern, focal areas of
hemorrhage and necrosis could often be seen. The tumour cells
were normal in size but contain a large amount of eosinophilic
cytoplasm in 6 patients (25%) were diagnosed malignant SPT
because there was histologic evidence of inﬁltration into sur-
rounding pancreatic tissue and capsular invasion. No patients had
lymph node metastases. Immunohistochemical analysis were per-
formed for 14 cases to conﬁrm the diagnosis of SPT. They were
typically positive for CD 99, vimentin, alpha 1 antitrypsin, neuron
speciﬁc enolase, beta-catenin and alpha 1 antichymotrypsin. Syn-
aptophysin, chromogranin A and Cytokeratin were expressed only
focally in few tumours (Table 4) (Figs. 6e9).
3.2.5. Follow up
Neither postoperative chemotherapy nor radiotherapy has been
given to any patients. Follow up included clinical examination,Table 4
Immunohistochemistry for 14 cases compared with the results of recent series.
Our study Cai H
Strong positive Focal positive Negative
CD 99 14 (100%) 0 0
Vimentin 14 (100%) 0 0 26/2
Alpha 1 antitrypsin 12 (85.7%) 0 2 (14.3%) 26/2
Neuron speciﬁc enolase 13 (92.7%) 0 2 (7.1%) 23/2
Chromogranin A 0 2 (14.3%) 12 (85.7%) 0/15
Nuclear beta-catenin 12/1
Alpha1 antichymotrypsin
Progesterone receptors 14/1
Estrogen receptor 0/7
Synaptophysin 0 4 (28.6%) 10 71.4% 24/2
Cytokeratin 0 3 (21.4%) 11 (78.6%) 7/13tumourmarkers, liver functions, blood sugar, abdominal US, and CT.
The patients were followed up for a mean duration of 71.62 57. 29
months (range, 1e180 months), all patients except 2 patients (8.3%)
were alive, one died 5 months postoperatively due to acute supe-
rior mesenteric vascular occlusion and the other one died after 4
years due to recurrence with bad general condition. The estimated
1,3, and 5 year survival rate was 95%, 95%, and 88% respectively.
The recurrence rate was 2 among 24 patients (8.3%), the two
patients had SPC and developed local recurrence 5 years after
surgery. Reexploration with complete resection of the recurrent
lesion was done in one case (the size of recurrence was 20 cm,
diagnosed by abdominal CT andMRI, located at the area of pancreas
and invading the left lobe of the liver) whereas the other one died
before exploration (Fig. 10). At present, no patients has developed
diabetes or sign of pancreatic secretion impairment. Eighteen pa-
tients had a chance of pregnancy with normal labor.
There is no statistical difference in the age, sex, preoperative
tumour markers, tumour size, or tumour location between the
benign andmalignant groups. However, we found that back pain as
a clinical presentation is signiﬁcantly more in malignant group
(P ¼ 0.01). Peripancreatic inﬁltration, capsular invasion, perineural
inﬁltration and cellular atypia were signiﬁcantly present in the
malignant group. Recurrence rate andmortality rate were higher in
the malignant group (P ¼ 0.01) (Tables 1e3).
Table 5, and 6 Summarizes the recent published series of SPT of
the pancreas including this study.
4. Discussion
SPT represents an enigmatic tumour from which the origin,
prognosis and natural history are unknown. It had aroused a greatet al.40 Yu PF et al.29 Yang et al.33 Speer et al.39 Tipton
SG et al.25
7 (96%) 269/289 (93.1%) 179/219 (81.7%) 5/5 (100%) 11/13
6 (100%) 261/276 (94.6%) 187/197 (94.9%) 6/6 (100%)
4 (96%) 179/221 (81%) 111/156 (71.2% 6/6 (100%)
45/193 (23.3%) 42/187 22.5% 2/5%) (40 3/13
2 (100%) 1/1
215/237 (90.7%) 60/66 (90.9%)
5 (93%) 89/157 (56.7%) 60/118 (50.8%)
11/97 (11.3%)
5 (96%) 83/196 (42.3%) 49/151 (32.5%) 2/3 (66.6%) 2/13
(54%) 66/213 (31%) 56/171 (32.7%) 3/6 (50%) 1/13
Fig. 6. (a): Pseudopapillary pattern of growth (H&E staining 100). (b): Thin vascular structures covered by cuboidal cells with no cellular atypia (H&E staining 400).
Fig. 7. a, b): SPT showing para-nuclear dot like staining (CD99 immunohistochemical staining 400).
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were published, however, the pathogenesis and guidelines for SPT
management remain unclear.2e5,8 In the past 50 years, only 500
articles about this disease were published all over the world. A total
of 500 cases of SPT of the pancreas have been reported since 1959.
The incidence rate of SPT of the pancreas is 0.2e2.7% of exocrine
pancreatic neoplasm.2,4e8Fig. 8. a, b): SPT showing strong positive cytoplasmic reacSPT of the pancreas are common in young women especially
aged from 20 to 40 years.3e8,11e13 The average age of our study was
24.83  8.66 years (range, 12e52), younger than that reported by
Sheehan et al.19 (39 years, 24 patients) and Kim et al.12 (36 years,
114 patients). In our study, there was no correlation between ma-
lignant potential and the age or sex. Some studies reported that old
age at presentation of SPT or male sex can be regarded as predictortion (Vimentin immunohistochemical staining 200).
Fig. 9. a): SPT showing moderate positive cytoplasmic reaction (Synaptophysin immunohistochemical staining 200). (b): SPT showing negative reaction (Cytokeratin immuno-
histochemical staining 200).
Fig. 10. A 17 years old female presented by recurrent SPT, 5 years after pancreaticoduodenectomy. The recurrent mass was well capsulated about 25  15 cm in the area of the
pancreas and invading the left lobe of the liver. Complete resection of the recurrent lesion was done with left hepatectomy.
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Table 5
Clinicopathological features in recent series.
Years No Sex Age Size Location Clinical picture
H B T As P M J LW BP
Cheng et al.36 2005 22 22/0 27.3
11e65
9.5
2.5e25
Zhong et al.37 2006 20 18/2 25.3
13e48
8.2
3e17
Yang et al.33 2008 390 283/47 25.3
6e69
8.4
2e25
44% 51% 31% 37% 35.5% 2.6% 1.1% 3.4%
Yu PF et al.29 2010 553 494/59 27.2
6e71
7.8
1e25
39.9% 30.1% 24.1% 31.6% 37.6% 35.9% 3.6% 1.9% 3.6%
Kang CM et al.20 2006 33 28/5 32
17e57
6
4.7e13
14/33 7/33 12/33 13/33 12/33 5/33 0 4/33 1/33
Chen Xi et a24 2005 21 21/0 27.3
11e65
9.5
3e20
57.1% 42.9% 61.9% 33.3% 0 0 0
Yang F et al.38 2009 26 22/4 32.3
15e64
6.25
2e15
14/26 12/26 11/26 9/26 13/26 0 0 5/26
Speer et al.39 2012 11 7/4 14
9e17
5
3.5e12
5/11 1/11 5/11 73% 9% 0 18% 0
Kim HH et al.30 2011 30 26/4 30.5
9e66
6.2
1.25e15
53.3% 16.7% 30% 20% 50% 13.3% 0 0 0
Cai H et al.40 2011 33 30/3 29.2
1e59
4.9
2e15
14/33 19/33 21% 58% 15% 0 0 0
Yu P et al.26 2011 11 11/0 29.5
16e55
5.32
2e10
27.3% 72.7% 27.3% 36.4% 0 0 0 18.2%
Reddy S et al.11 2009 37 33/4 32
13e75
4.5
0.3e12
39% 19% 39% 13% 81% 0 0 10% 0
Yu CC et al.7 2007 26 25/26 23
13e57
7.5
3.8e15
42.3% 14.5% 23.1% 19.2% 38.5% 19.2% 7.7%
Kim CW et al.12 2011 114 98/16 36
11e75
4.2
1.2e15
43.9% 56.1% 39.5% 36.8% 12.3% 0.9% 0 3.5%
Matos JM et al.13 2009 21 20/1 34
13e60
5.5 7 5 9 24% 67% 10% 10%
Tipton SG et al.25 2006 14 13/1 30
15e57
7
4e16
9/14 4/14 1/14 1/14 1
Huang HL et al.41 2005 7 6/1 31
13e50
10.5
5e20
2 5 2 2 2
Peng CH et al.42 2006 25 25 33 9.25
2.5e25
14/25 5/25 6/25 2/25 13/25 3/25
Papavramidis T et al.8 2005 718 626/64 21.97
2e85
6.08
0.5e34.5
34% 14.8% 35.9% 15.5% 46.5% 34.8% 1.09% 0.93 3.89%
Our study 2012 24 22/2 24.83  8.66
(12e52)
9.2  5.3
(3e25)
12
(50%)
2
(8.3%)
10
(41.7%)
2
(8.3%)
20
(83.3%)
8
(33.3%
2
(8.3%)
3
(12.5%)
4
(16.7%)
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nant potential of SPTcannot be predicted before surgery by age, sex,
tumour size or tumour marker.14,22
The usual presentations of SPT are usually non speciﬁc and
include abdominal pain and palpable abdominal mass. Few pa-
tients developed jaundice owing to obstruction of the bile duct and
no symptoms of disturbed pancreatic exocrine function. Previous
studies have found that about 70e90% of patients presented with
symptoms.3e8,12,13 In our study, 22 patients (91.7%) had symptoms,
whereas two patients (8.3%) were diagnosed incidentally.
SPT are usually large lesions (>10 cm), well demarcated, and
may occur anywhere within the pancreas, that is easily diagnosed
by ordinary image examination as ultrasound, or CT. They usually
start as solid tumours and later undergo massive degeneration
giving rise to a cystic appearance on radiological imaging.23,24
Radiologically, SPTs have a wide range of appearance from solid
to cystic, but a well encapsulated mass, with solid and cystic
component has been identiﬁed as a typical imaging ﬁnding of
SPT.12,14 Sometimes, the origin of the tumour could not be clearly
conﬁrmed because it is large or it envelopes the surrounding
tissues.12,23e28
Yen et al.14 reported that there was no signiﬁcant difference
between benign and malignant SPT in the calciﬁcation pattern
(P¼ 0.09), the proportion of cystic or solid component (P¼ 0.19), or
pancreatic duct dilatation (P ¼ 0.687) as proved in our study.However, capsule morphology (complete, focal discontinuity, or
ill deﬁned) was signiﬁcantly different between the two groups
(P ¼ 0.05).14,27,28
SPT may occur anywhere within the pancreas.3e8,12,23e26
Papavramidis T et al.8 reported that the most common location of
the tumour is the tail of the pancreas (35.9%), then the head (34%),
the body (14.8%) and lastly the neck (1.01%). Yu PF et al.29 found that
most of tumours were distributed in the pancreatic head (39.8%),
with the tail (24.1%), body and tail (19.5%), body (11.2%), and neck
(3.6%). Yin et al.14 reported that there was no predominant location
of the SPT within the pancreas. 35.4% were located in the head, 4.8%
in the neck,18.3% in the body, and 20.7% in the tail. In our study, The
most common sites of the tumour were pancreatic head in 12 pa-
tients (50%), body in 2 patients (8.3%) and tail in 10 patients (41.7%)
but there was no signiﬁcant difference in the location between
malignant and benign SPT (P ¼ 0.53).
In this study, the SPT was single in all patients, and the mean
diameter of tumourwas 9.2 5.3 cm (range 3e25 cm). Papavramidis
T et al.8 found that the mean diameter of the tumour was 6.08 cm
(0.5e34.5 cm). Yu PF et al.29 found that the mean diameter of the
tumour was 7.87 cm (range 1e25 cm). Yin et al.14 found that large
tumour size> 6 cmmay suggest malignancy of SPT. Kang et al.20 re-
ported that the tumour diameter greater than 5 cm is a signiﬁcant
feature of the tumour predicting SPT and suggesting malignant
potential. Kim et al.30 reported that the mean tumour diameter was
Table 6
Surgical outcome and follow up in recent series.
year CT Operation Mean FU (m) Rec Surviv
C S CS PD DP CP LR TP O
Cheng et al.36 2005 50% 9.1% 40.9% 0 22 alive
Zhong et al.37 2006 20% 20% 45% 8% 44.4
9e120
0 3 died
Yang et al.33 2008 29.1% 32.1% 4.6% 30.8% 3.3% 1e170 3 5 died
Yu PF et al.29 2010 15.6% 24.3% 60.1% 25.7% 31.4% 6% 33% 0.6% 3.1% 49.2
1e209
3.6% 4 died
Kang CM et al.20 2006 10/33 17/33 6/33
Chen Xi et a24 2005 4/21 6/21 24 0
Yang F et al.38 2009 11/26 15/26 8/26 10/26 1/26 6/26 1/26 32.5
3e69
one One died
Speer et al.39 2012 4/11 5/11 2 16
0.6e70
one
Kim HH et al.30 2011 20% 26.7% 53.3% 6/30 13/30 1/30 10/30 58
6e187
0 No death
Cai H et al.40 2011 2/33 31/33 18% 33% 12% 24% 9% 12% 4e118 one No death
Yu P et al.26 2011 36.4% 63.6% 9.1% 45.5% 36.4% 0 45.4
5e90
no
Reddy S et al.11 2009 100% 14/36 20/36 1/36 1/36 58 one One died
Yu CC et al.7 2007 30.8% 26.9% 11.6% 23.1% 66
10.1e236.8
two Two died
Kim CW et al.12 2010 80% 34.2% 43.9% 14% 4.4% 57
11e177
4 patients No death
Matos JM et al.13 2009 5 9 6 55 no no
Tipton SG et al.25 2006 3 6 5 3 9 1 1 3e240 One 2 died
Huang HL et al.41 2005 100% 2 5 74
6e148
one
Peng CH et al.42 2006 8 5 2
Papavramidis T et al.8 2005 25.6% 39.9% 1.27% 21.88% 0.9% 2.53% 60 31 21 death
Our study 2012 3
(12.5%)
4
(16.7%)
17
(70.8%)
12
(50%)
10
(41.7%)
2
(8.3%)
71.62  57.29
(1e180)
2
(8.3%)
2
(8.3%)
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tumour size > 5 cm has been recently reported to be predictive of
malignancy of SPT, we did notﬁnd any clinical parameter that predict
SPC, the same ﬁnding as reported by Kim et al.12
Despite the large SPT size or vascular inﬁltration at the time of
diagnosis, surgical resection is usually possible and curative.
Therefore, complete aggressive resection is the treatment of choice
for SPT even in presence of metastases. Resection of distant me-
tastases should be done at the time of primary resection. Resection
should also be tried for recurrences. Extensive lymphadenectomy
was not necessary because none of the patients in this study had
lymph node inﬁltration. The rarity of nodal metastases is consistent
with other studies.21,22 Although the tumour is large and can invade
surrounding tissue, surgical resection is necessary. Recurrence of
SPT of the pancreas after complete local resection has not been
reported.24 About 15% of patients are reported to have liver
metastasis, which can be removed operatively3,12,24
SPT was classiﬁed according to the WHO as either SPT with an
uncertain potential for malignancy or solid pseudopapillary carci-
noma SPC.1,2 Although criteria of malignancy have not yet been
clearly established, it appears that unequivocal perineural invasion,
angioinvasion, deep invasion into the surrounding tissue or distant
metastasis indicate malignant behavior, and such lesions should be
classiﬁed as SPC. a high degree of nuclear atypia, mitotic activity
and prominence of necrobiotic cell nests (cells with pyknotic nuclei
and eosinophilic cytoplasm) were reported to be associated with
malignancy.1 Although deep pancreatic invasion, perineural inﬁl-
tration, vascular invasion, high degree of cellular atypia have been
related to malignant potential,1e3,8,12,14,20,30 other studies reported
that histopathologic features suggesting malignant potential were
non speciﬁc and malignant behavior (recurrence and metastasis)
could not be completely excluded even in the absence of patho-
logical feature suggesting malignant potential.6,31,32 We found that
the incidence of SPC was 25%, which is in good agreement withthe 14.4%e33% reported previously.12,20,33 Local invasion of peri-
pancreatic tissue was the most common malignant feature. How-
ever, according to this study, 2 patients among 24 patients (8.3%)
with SPT were found to have malignant behavior (recurrence and
metastasis), and both were among the patients group that had a
histopathology suggesting malignant potential (2/6, 33.3%).
No over-expression of estrogen hormone nor evidence for endo-
crinal therapy has been reported. No studies address that chemo-
therapy or radiotherapy has a role in treatment of SPT.1e3,8,12,30
The prognosis of SPT patients even with local recurrence and
metastasis or invasion is good. SPT is limited to pancreas in over
95% of its patients and can be radically resected.3,12,34,35 Its local
recurrence rate is less than 10% and usually occur within 4 years
after surgery.8,12,29,34 In our study, the patients were followed up for
a mean duration of 71.62  57.29 months (range, 1e180 months),
the recurrence rate was 2 among 24 patients (8.3%), the two pa-
tients had SPC and developed local recurrence 5 years after surgery.
Reexploration and the recurrent lesion was removed completely in
one case (the size of recurrencewas 20 cm, diagnosed by abdominal
CT and MRI. It was located at the area of pancreas and invading the
left lobe of the liver) whereas the other one died before exploration.
Kim et al.12 reported that most patients who developed recurrence
had metastasis at the ﬁrst operation, tumour rupture, or adjacent
organ invasion. There was no recurrence related to perineural in-
vasion, or angioinvasion. However, Reddy et al.11 and Sperti et al.34
reported that the recurrence related to perineural invasion, and
angioinvasion. Because of rarity of SPT and its indolent character,
multicenteric large studies with long term follow up are needed to
determine the risk factors related to recurrence.
In this study, all patients except 2 (8.3%) were alive, one died 5
months postoperatively due to acute superior mesenteric vascular
occlusion and the other one died after 4 years due to recurrencewith
bad general condition. The estimated1,3, and5 year survival ratewas
95%, 95%, and 88% respectively. Papavramidis T and Papavramidis S
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is about 95%.12 Yu PF et al. found that the estimated 1, 3, and 5 year
survival was 99.4%, 97.5%, and 96.9% respectively.
The limitations of this study were the retrospective design and
the limited number of cases. Because of rarity of SPT and its indo-
lent character, multicenteric large studies with long term follow up
are needed to determine the risk factors related to recurrence and
survival. The role of chemotherapy and radiotherapy not studied in
this study.
5. Conclusions
SPT of the pancreas is a rare neoplasm with low malignant po-
tential, but the incidence is increasing. Large tumour of the
pancreas among young women with solid and cystic areas should
be highly suspected as SPT. Aggressive surgical resection can result
in good prognosis in these patients even in the presence of
metastasis. Close follow up is necessary in patients with malignant
behavior and surgical resection is required in patients with recur-
rence. long term survival is excellent even after recurrence if sur-
gical resection is performed.
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